Seeking Alpha


View as an RSS Feed
View Pannobhaso's Articles BY TICKER:
  • Benitec's DdRNAi Targeting Fight Against HIV
    Wed, Aug. 13 BTEBY 12 Comments


    • HIV market to be worth $16B by 2019.
    • Calimmune, Johnson & Johnson and many universities pioneering pre-clinical and clinical studies using ddRNAi to treat HIV.
    • Benitec Biopharma has seminal ddRNAi patents.
    • One clinical trial completed and two more currently active.
    • A one-off treatment could provide a lifetime of protection against HIV/AIDS.
  • Alnylam And Benitec
    Fri, Jul. 25 ALNY, ARWR, BTEBY 8 Comments
  • TT-034: Not A Binary Outcome For Benitec
    Thu, Jul. 24 BTEBY, BNIKF 10 Comments
  • Benitec: The Health Payer's Dream Biotech
    Wed, Mar. 12 BNIKF 123 Comments


    • The cost of health care has been forecast to escalate significantly.
    • A change in the health care paradigm is required if health payers are to keep pace with the costs of disease standards of care.
    • Benitec Biopharma is one company with the paradigm-changing technology that could be the answer to health payers' prayers.
    • Early adopters of the new health care model, such as Benitec Biopharma, are set to corner the market for several major disease types.
    • There is an opportunity for retail and corporate investors as big pharma may get the message and start investing in the new paradigm.